BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 9898309
• 负责人: Shyam S Mohapatra
• 金额: --
• 依托单位: JAMES A. HALEY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-04-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9898309
• 关键词: Academy; Age; American; Antiviral Agents; Asthma; Award; Basic Science; Biological; Biological Assay; Biology; Biotechnology; Birds; CCL20 gene; Cancer Patient; Cardiopulmonary; Clinical; Collaborations; Combined Modality Therapy; Development; Diagnosis; Diagnostic; Disease; Education; Educational process of instructing; Elderly; Endowment; Engineering; Extramural Activities; FDA approved; Florida; Formulation; Four-dimensional; Funding; Future; Genomic approach; Genomics; Goals; Grant Review; Health; Hospitalization; Hospitals; Hypersensitivity; Illness impact; Immunology; Individual; Inflammation; Inflammatory; Injury; Institutes; International; Iraq; Journals; Knowledge; Lead; Leadership; Legal patent; Literature; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of lung; Medical; Medicine; Mesenchymal Stem Cells; Methods; MicroRNAs; Military Personnel; Modeling; Nanotechnology; Nature; Nerve Regeneration; Nursing Faculty; Peptides; Pharmaceutical Preparations; Phospholipids; Pneumonia; Publications; Rattus; Reporting; Research; Research Activity; Research Personnel; Research Support; Respiratory Syncytial Virus Infections; Respiratory syncytial virus; Scientist; Seminal; Small Interfering RNA; System; TBI treatment; Technology; Testing; Therapeutic; Training; Translational Research; Translations; Traumatic Brain Injury; United States National Institutes of Health; Universities; Veterans; Viral; Viral Respiratory Tract Infection; Virus Diseases; Work; age group; base; bench to bedside; cancer diagnosis; cancer therapy; career; clinical diagnostics; clinical investigation; combinatorial; drug efficacy; efficacy testing; evidence base; experience; graduate student; high risk; human disease; inhibitor/antagonist; innovation; nano; nanofiber; nanomedicine; nanoscale; neoplasm registry; novel; novel diagnostics; novel therapeutics; personalized cancer therapy; prevent; professor; programs; prophylactic; scaffold; stem cell therapy; translational medicine

This proposal seeks to renew Research Career Scientist Award held by Dr. Shyam S Mohapatra at the James A. Haley VA Hospital in Tampa, Florida since 2007. He is a Distinguished Health Professor and the Director of the Division of Translational Medicine- Center for Research and Education in Nanobioengineering at the VA-affiliated academic center- the University of South Florida. He is recognized nationally and internationally for his contribution to the field of nanoscale biomedical diagnostics and therapeutics in relation to a number inflammatory diseases including asthma, viral infections, traumatic brain injury (TBI) and cancers. He has received substantial extramural research support including awards from the NIH, DOA, ONR, Department of Veterans’ Affairs and Florida Department of Health. In addition to the two international awards early in his academic career, he is the recipient of the USF biotechnology award, the Sigma XI award, TBTF Technology Leadership Award, Excellence in Research and Innovation award and Global Corporate award in Nanotechnology. He has contributed substantially to scientific literature including over 170 publications, some in very high impact journals such as Nature Medicine and journal of Clinical Investigation, and has >30 U.S. and foreign patents. He is a Fellow of the National Academy of Inventors and of the American Institute of Medical and Biological Engineering. In recognition of his contribution to the biomedical nanotechnology, he was inducted to the “Florida Inventors’ Hall of Fame” in 2014. In addition, he has devoted his efforts in training clinical fellows and graduate students in research and teaching at the VA hospital. Dr. Mohapatra has been a research investigator at the VA Hospital since 1996 and has been funded with the Merit Review Award focused on respiratory syncytial virus (RSV) infection since 1999. His lab has contributed substantially to the translation of new genomic approaches such as those involving small-interfering RNAs (siRNA) and microRNAS and emerging field of nanomedicine, with the premise that these technologies will aid in developing new methods for diagnosis and therapy of diseases afflicting Veterans. Current research activities to be supported by this RCS Award are as follows. Project #1. Develop new prophylactic and/or therapeutic approaches using novel nanoscale technologies, which are effective against both primary and secondary RSV infections, broadly useful in all age groups and inexpensive. His proposed merit review project (A1 revision to be submitted) aims to develop a simple, smart and scalable nanomicellar system that combines novel targets for viral fusion-, cellular antiviral- and replication-inhibitors. Project #2. Investigate the potential of a novel combinatorial therapeutic approach in a rat model of moderate TBI that includes (i) a treatment to reduce inflammation (local and systemic) using a nano-formulated siRNA against a recently discovered target, CCL20, and (ii) a second treatment to promote neuroregeneration by mesenchymal stem cell therapy. Project #3. Develop a novel cellomic-based personalized cancer treatment approach using a four-dimensional (4D) tumoroid culture platform. The assay can be used by itself or as an adjunct assay to currently practiced genomic testing, which predicts drug(s) that will be the most appropriate for the treatment of that patient’s cancer. These innovative applications of nanomedicine approaches taken together are expected to lead to high impact therapies for Veterans and other Americans in need. !

这项建议旨在更新Shyam S Mohapatra博士在 詹姆斯A。自2007年以来，在佛罗里达的坦帕的Haley VA医院。他是一个杰出的健康 教授和转化医学部主任-研究中心和 在VA附属学术中心的纳米生物工程教育-南大学 佛罗里达。他因在纳米尺度领域的贡献而在国内和国际上得到认可。 生物医学诊断和治疗与许多炎性疾病，包括 哮喘、病毒感染、创伤性脑损伤（TBI）和癌症。他收到了大量 校外研究支持，包括来自NIH，DOA，ONR，退伍军人部的奖项 事务和佛罗里达卫生部。除了早期的两个国际奖项外， 在学术生涯中，他是USF生物技术奖，Sigma XI奖，TBTF 技术领导奖，卓越研究和创新奖和全球 纳米技术企业奖。他对科学文献作出了重大贡献 包括170多篇出版物，其中一些发表在影响力很大的期刊上，如《自然医学》和《自然》杂志。 临床研究杂志，并拥有超过30项美国和外国专利。他是一个研究员的 美国国家发明家学会和美国医学和生物研究所 工程.为了表彰他对生物医学纳米技术的贡献， 2014年入选“佛罗里达发明家名人堂”此外，他还致力于训练， 临床研究员和研究生在退伍军人医院的研究和教学。 Mohapatra博士自1996年以来一直是VA医院的研究调查员， 获得了重点关注呼吸道合胞病毒（RSV）感染的优异评审奖的资助 自1999年以来。他的实验室为新的基因组方法的翻译做出了巨大贡献 例如涉及小干扰RNA（siRNA）和microRNAS的那些，以及 纳米医学，前提是这些技术将有助于开发新的方法， 诊断和治疗困扰退伍军人的疾病。目前需要支持的研究活动 本次RCS获奖情况如下。 一号工程。开发新的预防和/或治疗方法，使用新的纳米 这些技术对原发性和继发性RSV感染都有效， 适合所有年龄段，价格便宜。他提议的绩效审查项目（A1修订版， 提交）旨在开发一种简单，智能和可扩展的纳米胶束系统， 病毒融合、细胞抗病毒和复制抑制剂的靶点。 二号工程。研究一种新的组合治疗方法在大鼠中的潜力 中度TBI的模型，其包括（i）使用以下治疗以减少炎症（局部和全身）： 针对最近发现的靶标CCL 20的纳米配制的siRNA，和（ii）第二治疗 通过间充质干细胞疗法促进神经再生。 第三个项目。开发一种基于细胞组学的个性化癌症治疗方法， 四维（4D）类肿瘤培养平台。该检测试剂盒可单独使用或作为辅助试剂使用 目前实行的基因组测试，预测药物，将是最 适合治疗病人的癌症 这些纳米医学方法的创新应用预计将 为退伍军人和其他有需要的美国人提供高影响力的治疗。!